TCGA-OU-A5PI-01
Adrenocortical Carcinoma · Adrenocortical Carcinoma · Adrenocortical Carcinoma, Usual Type
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Adrenocortical Carcinoma
- cancer_type_detailed
- Adrenocortical Carcinoma
- subtype
- Adrenocortical Carcinoma, Usual Type
- cancer_type
- Adrenocortical Carcinoma
- cancer_type_detailed
- Adrenocortical Carcinoma
- subtype
- Adrenocortical Carcinoma, Usual Type
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- HEDGEHOG_SIGNALING+0.383
- UV_RESPONSE_DN+0.345
- CHOLESTEROL_HOMEOSTASIS+0.341
- NOTCH_SIGNALING+0.314
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.216
- ANDROGEN_RESPONSE+0.184
- HEME_METABOLISM+0.165
- APICAL_SURFACE+0.156
- ESTROGEN_RESPONSE_EARLY+0.153
- KRAS_SIGNALING_DN+0.136
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.379
- DNA_REPAIR-0.317
- MYC_TARGETS_V1-0.310
- ALLOGRAFT_REJECTION-0.267
- IL2_STAT5_SIGNALING-0.199
- COMPLEMENT-0.185
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.185
- E2F_TARGETS-0.182
- INTERFERON_ALPHA_RESPONSE-0.153
- PI3K_AKT_MTOR_SIGNALING-0.152
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 544dbca2-f436-4cb7-9e11-572ead91d28d | — | — | 0.754 |
| 2 | SRR8613758 | — | C | 0.660 |
| 3 | SRR8613703 | — | D | 0.660 |
| 4 | s0122297 | — | — | 0.657 |
| 5 | TCGA-A1-A0SH-01A-11R-A084-07 | — | A | 0.657 |
| 6 | SRR934822 | — | — | 0.654 |
| 7 | MNG126 | — | — | 0.652 |
| 8 | f825534d-5882-4efe-a32e-af56741854f6 | — | — | 0.649 |
| 9 | MNG792 | — | — | 0.648 |
| 10 | TCGA-A2-A3KD-01A-12R-A213-07 | — | A | 0.645 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| HEDGEHOG_SIGNALING | 0.383 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.345 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.341 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.314 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.216 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.184 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.165 | Temsirolimus | — uncovered |
| APICAL_SURFACE | 0.156 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.153 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.136 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.125 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.116 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.115 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.115 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.112 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.079 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.077 | Cobimetinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.077 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.066 | Inavolisib | — uncovered |
| APOPTOSIS | 0.059 | Idelalisib | — uncovered |